Published in J Biol Chem on January 08, 2010
The AMPK signalling pathway coordinates cell growth, autophagy and metabolism. Nat Cell Biol (2011) 6.83
Epigenetic protein families: a new frontier for drug discovery. Nat Rev Drug Discov (2012) 6.70
Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. Cell (2012) 5.71
Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice. J Gerontol A Biol Sci Med Sci (2010) 5.54
Sirtuins as regulators of metabolism and healthspan. Nat Rev Mol Cell Biol (2012) 4.86
Absence of effects of Sir2 overexpression on lifespan in C. elegans and Drosophila. Nature (2011) 4.48
Use of cells expressing gamma subunit variants to identify diverse mechanisms of AMPK activation. Cell Metab (2010) 4.14
Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab (2011) 3.69
SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Cell Metab (2012) 3.69
Evidence for a common mechanism of SIRT1 regulation by allosteric activators. Science (2013) 3.40
Ten years of NAD-dependent SIR2 family deacetylases: implications for metabolic diseases. Trends Pharmacol Sci (2010) 3.05
Sirt1 improves healthy ageing and protects from metabolic syndrome-associated cancer. Nat Commun (2010) 2.97
PARP-1 inhibition increases mitochondrial metabolism through SIRT1 activation. Cell Metab (2011) 2.94
The promise and peril of chemical probes. Nat Chem Biol (2015) 2.64
Conserved role of SIRT1 orthologs in fasting-dependent inhibition of the lipid/cholesterol regulator SREBP. Genes Dev (2010) 2.55
Can autophagy promote longevity? Nat Cell Biol (2010) 2.55
Small molecule SIRT1 activators for the treatment of aging and age-related diseases. Trends Pharmacol Sci (2014) 2.37
Spermidine and resveratrol induce autophagy by distinct pathways converging on the acetylproteome. J Cell Biol (2011) 2.23
Are sirtuins viable targets for improving healthspan and lifespan? Nat Rev Drug Discov (2012) 2.22
Silent information regulator 1 protects the heart from ischemia/reperfusion. Circulation (2010) 2.19
Hormonal regulation of hepatic glucose production in health and disease. Cell Metab (2011) 2.12
Sirtuins mediate mammalian metabolic responses to nutrient availability. Nat Rev Endocrinol (2012) 2.12
SIRT1: recent lessons from mouse models. Nat Rev Cancer (2010) 2.07
Mechanism of inhibition of the human sirtuin enzyme SIRT3 by nicotinamide: computational and experimental studies. PLoS One (2014) 2.02
Sirtuin 1 and sirtuin 3: physiological modulators of metabolism. Physiol Rev (2012) 1.99
AMP-activated protein kinase and its downstream transcriptional pathways. Cell Mol Life Sci (2010) 1.95
Regulation of SIRT1 in cellular functions: role of polyphenols. Arch Biochem Biophys (2010) 1.91
Suberoylanilide hydroxamic acid (vorinostat) up-regulates progranulin transcription: rational therapeutic approach to frontotemporal dementia. J Biol Chem (2011) 1.88
Targeting sirtuin 1 to improve metabolism: all you need is NAD(+)? Pharmacol Rev (2011) 1.85
Illuminating insights into firefly luciferase and other bioluminescent reporters used in chemical biology. Chem Biol (2010) 1.83
SRT1720 improves survival and healthspan of obese mice. Sci Rep (2011) 1.81
Metabolic networks of longevity. Cell (2010) 1.79
SIRT1 activation by small molecules: kinetic and biophysical evidence for direct interaction of enzyme and activator. J Biol Chem (2010) 1.75
Resveratrol confers endothelial protection via activation of the antioxidant transcription factor Nrf2. Am J Physiol Heart Circ Physiol (2010) 1.73
Agrp neurons mediate Sirt1's action on the melanocortin system and energy balance: roles for Sirt1 in neuronal firing and synaptic plasticity. J Neurosci (2010) 1.73
Pilot study of resveratrol in older adults with impaired glucose tolerance. J Gerontol A Biol Sci Med Sci (2012) 1.72
The pros and cons of phytoestrogens. Front Neuroendocrinol (2010) 1.69
Pharmacological approaches to restore mitochondrial function. Nat Rev Drug Discov (2013) 1.66
Sirtuin 1 in lipid metabolism and obesity. Ann Med (2011) 1.65
A novel inverse relationship between metformin-triggered AMPK-SIRT1 signaling and p53 protein abundance in high glucose-exposed HepG2 cells. Am J Physiol Cell Physiol (2012) 1.62
SIRT3 deficiency exacerbates ischemia-reperfusion injury: implication for aged hearts. Am J Physiol Heart Circ Physiol (2014) 1.60
Regulation of mitochondrial biogenesis. Essays Biochem (2010) 1.58
Novel insights of dietary polyphenols and obesity. J Nutr Biochem (2014) 1.58
Of mice and men: the benefits of caloric restriction, exercise, and mimetics. Ageing Res Rev (2011) 1.47
Turning enzymes ON with small molecules. Nat Chem Biol (2010) 1.47
Acetylation-deacetylation of the transcription factor Nrf2 (nuclear factor erythroid 2-related factor 2) regulates its transcriptional activity and nucleocytoplasmic localization. J Biol Chem (2010) 1.45
Genome-environment interactions that modulate aging: powerful targets for drug discovery. Pharmacol Rev (2011) 1.42
The SIRT1 activator SRT1720 extends lifespan and improves health of mice fed a standard diet. Cell Rep (2014) 1.42
Combinatorial latency reactivation for HIV-1 subtypes and variants. J Virol (2010) 1.40
Resveratrol: French paradox revisited. Front Pharmacol (2012) 1.40
Effects of resveratrol and SIRT1 on PGC-1α activity and mitochondrial biogenesis: a reevaluation. PLoS Biol (2013) 1.40
Resveratrol, sirtuins, and the promise of a DR mimetic. Mech Ageing Dev (2010) 1.39
SirT1 regulates adipose tissue inflammation. Diabetes (2011) 1.39
NAD(+) Metabolism and the Control of Energy Homeostasis: A Balancing Act between Mitochondria and the Nucleus. Cell Metab (2015) 1.38
Lysine deacetylation in ischaemic preconditioning: the role of SIRT1. Cardiovasc Res (2010) 1.38
SIRT1 deacetylase in SF1 neurons protects against metabolic imbalance. Cell Metab (2011) 1.37
Sirtuins: guardians of mammalian healthspan. Trends Genet (2014) 1.36
Negative regulation of STAT3 protein-mediated cellular respiration by SIRT1 protein. J Biol Chem (2011) 1.35
SIRT1 reduces endothelial activation without affecting vascular function in ApoE-/- mice. Aging (Albany NY) (2010) 1.32
ERK activation by the polyphenols fisetin and resveratrol provides neuroprotection in multiple models of Huntington's disease. Hum Mol Genet (2010) 1.32
Aging and osteoarthritis. Curr Opin Rheumatol (2011) 1.31
Small-molecule allosteric activators of sirtuins. Annu Rev Pharmacol Toxicol (2013) 1.31
T cell replicative senescence in human aging. Curr Pharm Des (2013) 1.31
Ursolic acid protects diabetic mice against monocyte dysfunction and accelerated atherosclerosis. Atherosclerosis (2011) 1.31
Activation of Sirt1 by resveratrol inhibits TNF-α induced inflammation in fibroblasts. PLoS One (2011) 1.29
Nutraceutical antioxidants as novel neuroprotective agents. Molecules (2010) 1.29
FoxO1 mediates an autofeedback loop regulating SIRT1 expression. J Biol Chem (2010) 1.27
Pro-autophagic polyphenols reduce the acetylation of cytoplasmic proteins. Cell Cycle (2012) 1.27
Skeletal muscle mitochondria and aging: a review. J Aging Res (2012) 1.27
A molecular mechanism for direct sirtuin activation by resveratrol. PLoS One (2012) 1.26
Pleiotropic mechanisms facilitated by resveratrol and its metabolites. Biochem J (2010) 1.26
Resveratrol as a calorie restriction mimetic: therapeutic implications. Trends Cell Biol (2012) 1.26
Peptide switch is essential for Sirt1 deacetylase activity. Mol Cell (2011) 1.26
SIRT1 and energy metabolism. Acta Biochim Biophys Sin (Shanghai) (2013) 1.25
Dietary interventions to extend life span and health span based on calorie restriction. J Gerontol A Biol Sci Med Sci (2010) 1.23
Coming of age: molecular drivers of aging and therapeutic opportunities. J Clin Invest (2013) 1.22
MicroRNA Regulation of SIRT1. Front Physiol (2012) 1.21
High-yield resveratrol production in engineered Escherichia coli. Appl Environ Microbiol (2011) 1.21
Role of transcription factor acetylation in diabetic kidney disease. Diabetes (2014) 1.20
Role of deleted in breast cancer 1 (DBC1) protein in SIRT1 deacetylase activation induced by protein kinase A and AMP-activated protein kinase. J Biol Chem (2012) 1.19
Sirtuin activators and inhibitors. Biofactors (2012) 1.19
Elevated microRNA-34a in obesity reduces NAD+ levels and SIRT1 activity by directly targeting NAMPT. Aging Cell (2013) 1.19
Nutrient sensing, autophagy, and diabetic nephropathy. Diabetes (2012) 1.19
Pathways for ischemic cytoprotection: role of sirtuins in caloric restriction, resveratrol, and ischemic preconditioning. J Cereb Blood Flow Metab (2011) 1.18
Vascular aging: chronic oxidative stress and impairment of redox signaling-consequences for vascular homeostasis and disease. Ann Med (2012) 1.18
Mammalian sirtuins and energy metabolism. Int J Biol Sci (2011) 1.17
Restoration of altered microRNA expression in the ischemic heart with resveratrol. PLoS One (2010) 1.17
The role of mammalian sirtuins in the regulation of metabolism, aging, and longevity. Handb Exp Pharmacol (2011) 1.16
Herbal therapies for type 2 diabetes mellitus: chemistry, biology, and potential application of selected plants and compounds. Evid Based Complement Alternat Med (2013) 1.16
Protective effects and mechanisms of sirtuins in the nervous system. Prog Neurobiol (2011) 1.14
Flavonoid apigenin is an inhibitor of the NAD+ ase CD38: implications for cellular NAD+ metabolism, protein acetylation, and treatment of metabolic syndrome. Diabetes (2012) 1.14
Hyperactive S6K1 mediates oxidative stress and endothelial dysfunction in aging: inhibition by resveratrol. PLoS One (2011) 1.12
NAD+ as a signaling molecule modulating metabolism. Cold Spring Harb Symp Quant Biol (2012) 1.12
NAD⁺ metabolism: a therapeutic target for age-related metabolic disease. Crit Rev Biochem Mol Biol (2013) 1.11
Protective effects of sirtuins in cardiovascular diseases: from bench to bedside. Eur Heart J (2015) 1.11
SIRT1 as a therapeutic target in inflammaging of the pulmonary disease. Prev Med (2011) 1.10
Resveratrol engages AMPK to attenuate ERK and mTOR signaling in sensory neurons and inhibits incision-induced acute and chronic pain. Mol Pain (2012) 1.10
Resveratrol mitigates lipopolysaccharide- and Aβ-mediated microglial inflammation by inhibiting the TLR4/NF-κB/STAT signaling cascade. J Neurochem (2011) 1.10
Sirtuin deacetylases in neurodegenerative diseases of aging. Cell Res (2013) 1.09
SIRT1 contains N- and C-terminal regions that potentiate deacetylase activity. J Biol Chem (2011) 1.09
Resveratrol improves health and survival of mice on a high-calorie diet. Nature (2006) 20.91
Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell (2006) 19.16
hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell (2001) 15.97
Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell (2001) 15.05
Increased dosage of a sir-2 gene extends lifespan in Caenorhabditis elegans. Nature (2001) 14.44
The SIR2/3/4 complex and SIR2 alone promote longevity in Saccharomyces cerevisiae by two different mechanisms. Genes Dev (1999) 14.43
Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase. Science (2004) 11.39
Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature (2007) 10.21
Sir2 mediates longevity in the fly through a pathway related to calorie restriction. Proc Natl Acad Sci U S A (2004) 9.25
The establishment, inheritance, and function of silenced chromatin in Saccharomyces cerevisiae. Annu Rev Biochem (2003) 7.22
Sirtuins deacetylate and activate mammalian acetyl-CoA synthetases. Proc Natl Acad Sci U S A (2006) 7.00
Human SIR2 deacetylates p53 and antagonizes PML/p53-induced cellular senescence. EMBO J (2002) 6.37
Specific SIRT1 activation mimics low energy levels and protects against diet-induced metabolic disorders by enhancing fat oxidation. Cell Metab (2008) 5.44
Increased dosage of mammalian Sir2 in pancreatic beta cells enhances glucose-stimulated insulin secretion in mice. Cell Metab (2005) 5.39
Substrate-specific activation of sirtuins by resveratrol. J Biol Chem (2005) 5.28
SirT1 gain of function increases energy efficiency and prevents diabetes in mice. Cell Metab (2008) 4.89
Mechanism of human SIRT1 activation by resveratrol. J Biol Chem (2005) 4.86
Sir2-dependent activation of acetyl-CoA synthetase by deacetylation of active lysine. Science (2002) 4.61
The biochemistry of sirtuins. Annu Rev Biochem (2006) 4.32
Calorie restriction increases muscle mitochondrial biogenesis in healthy humans. PLoS Med (2007) 3.92
AMP-activated protein kinase-deficient mice are resistant to the metabolic effects of resveratrol. Diabetes (2009) 3.39
Insulin resistance as a predictor of age-related diseases. J Clin Endocrinol Metab (2001) 3.31
Resveratrol is not a direct activator of SIRT1 enzyme activity. Chem Biol Drug Des (2009) 3.20
The molecular biology of the SIR proteins. Gene (2001) 3.05
Role for human SIRT2 NAD-dependent deacetylase activity in control of mitotic exit in the cell cycle. Mol Cell Biol (2003) 2.79
Discovery of indoles as potent and selective inhibitors of the deacetylase SIRT1. J Med Chem (2005) 2.77
Substrate specificity and kinetic mechanism of the Sir2 family of NAD+-dependent histone/protein deacetylases. Biochemistry (2004) 2.11
Molecular characterization of human acetyl-CoA synthetase, an enzyme regulated by sterol regulatory element-binding proteins. J Biol Chem (2000) 2.00
SIRT1 and insulin resistance. Nat Rev Endocrinol (2009) 1.96
Small molecule activators of SIRT1 replicate signaling pathways triggered by calorie restriction in vivo. BMC Syst Biol (2009) 1.94
Mechanisms and molecular probes of sirtuins. Chem Biol (2008) 1.90
Mechanism of nicotinamide inhibition and transglycosidation by Sir2 histone/protein deacetylases. J Biol Chem (2003) 1.87
Caloric restriction reverses hepatic insulin resistance in aging rats by decreasing visceral fat. J Clin Invest (1998) 1.82
Glucose tolerance and skeletal muscle gene expression in response to alternate day fasting. Obes Res (2005) 1.69
Treatment with SRT1720, a SIRT1 activator, ameliorates fatty liver with reduced expression of lipogenic enzymes in MSG mice. Am J Physiol Endocrinol Metab (2009) 1.68
Resveratrol, an activator of SIRT1, upregulates sarcoplasmic calcium ATPase and improves cardiac function in diabetic cardiomyopathy. Am J Physiol Heart Circ Physiol (2009) 1.44
Central administration of resveratrol improves diet-induced diabetes. Endocrinology (2009) 1.30
Identification and characterization of a novel p300-mediated p53 acetylation site, lysine 305. J Biol Chem (2003) 1.28
Activation of SIRT1 by resveratrol induces KLF2 expression conferring an endothelial vasoprotective phenotype. Cardiovasc Res (2009) 1.27
Sirtuins: a conserved key unlocking AceCS activity. Trends Biochem Sci (2006) 1.19
SIR2: the biochemical mechanism of NAD(+)-dependent protein deacetylation and ADP-ribosyl enzyme intermediates. Curr Med Chem (2004) 1.17
Sir2 deacetylases exhibit nucleophilic participation of acetyl-lysine in NAD+ cleavage. J Am Chem Soc (2007) 1.14
Sirtuins as novel targets for Alzheimer's disease and other neurodegenerative disorders: experimental and genetic evidence. J Alzheimers Dis (2010) 1.07
Screening for positive allosteric modulators of biological targets. Drug Discov Today (2006) 0.93
Purification of recombinant p53 from Sf9 insect cells. Methods Mol Biol (2003) 0.88
Kinetic properties and structural characterization of highly purified acetyl-CoA synthetase from bovine heart and tissue distribution of the enzyme in rat tissues. Tohoku J Exp Med (1995) 0.88
Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med (2010) 15.71
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med (2013) 11.93
Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol (2011) 8.66
Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol (2009) 7.04
Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA (2010) 6.65
CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood (2004) 4.05
Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol (2009) 3.69
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial. Lancet Oncol (2013) 3.56
Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol (2008) 3.49
Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial. Lancet Oncol (2013) 3.40
Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer. J Clin Oncol (2006) 3.24
Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer--pooled analysis from three multicenter, randomized, controlled trials using individual patient data. J Clin Oncol (2004) 3.16
Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271. Cancer Res (2008) 3.11
Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. Lancet Oncol (2013) 3.11
Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. Lancet Oncol (2012) 3.02
Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. J Clin Oncol (2007) 2.80
Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia. Nat Struct Mol Biol (2007) 2.76
Beaked whales respond to simulated and actual navy sonar. PLoS One (2011) 2.73
Non-operative treatment after neoadjuvant chemoradiotherapy for rectal cancer. Lancet Oncol (2007) 2.69
Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study. J Natl Cancer Inst (2007) 2.65
Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study. J Clin Oncol (2014) 2.64
The value of routine serum carcino-embryonic antigen measurement and computed tomography in the surveillance of patients after adjuvant chemotherapy for colorectal cancer. J Clin Oncol (2004) 2.62
Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancer. J Natl Cancer Inst (2012) 2.49
Tumor stage after neoadjuvant chemotherapy determines survival after surgery for adenocarcinoma of the esophagus and esophagogastric junction. J Clin Oncol (2014) 2.41
Influence of guidelines on CPR decisions: an audit of clerking proforma. Clin Med (2004) 2.39
Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial. Lancet Oncol (2010) 2.28
The role of probiotics in aquaculture. Vet Microbiol (2006) 2.27
Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. J Clin Oncol (2010) 2.23
High-resolution dynamics of the transcriptional response to nutrition in Drosophila: a key role for dFOXO. Physiol Genomics (2006) 2.18
Bleeding in cardiac surgery: the use of aprotinin does not affect survival. J Thorac Cardiovasc Surg (2008) 2.15
Discovery of a novel and potent class of FabI-directed antibacterial agents. Antimicrob Agents Chemother (2002) 2.14
Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III). J Clin Oncol (2012) 2.07
Guidelines for the management of oesophageal and gastric cancer. Gut (2011) 2.05
Crystal structure of the herpes simplex virus 1 DNA polymerase. J Biol Chem (2006) 1.98
Potential regional differences for the tolerability profiles of fluoropyrimidines. J Clin Oncol (2008) 1.92
Managing patients treated with bevacizumab combination therapy. Oncology (2005) 1.91
Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for advanced esophagogastric cancer: dose-finding study for the prospective multicenter, randomized, phase II/III REAL-3 trial. J Clin Oncol (2010) 1.83
Breast cancer risk after supradiaphragmatic radiotherapy for Hodgkin's lymphoma in England and Wales: a National Cohort Study. J Clin Oncol (2012) 1.77
Timing of surgery following preoperative therapy in rectal cancer: the need for a prospective randomized trial? Dis Colon Rectum (2011) 1.65
The UK NCRI MAGIC trial of perioperative chemotherapy in resectable gastric cancer: implications for clinical practice. Ann Surg Oncol (2007) 1.63
Mismatch repair deficient colorectal cancer in the era of personalized treatment. Nat Rev Clin Oncol (2010) 1.62
Discovery of antibacterial biotin carboxylase inhibitors by virtual screening and fragment-based approaches. ACS Chem Biol (2009) 1.60
Indole naphthyridinones as inhibitors of bacterial enoyl-ACP reductases FabI and FabK. J Med Chem (2003) 1.56
Estimating cetacean population density using fixed passive acoustic sensors: an example with Blainville's beaked whales. J Acoust Soc Am (2009) 1.54
Common variants at the MHC locus and at chromosome 16q24.1 predispose to Barrett's esophagus. Nat Genet (2012) 1.52
Insulin-like growth factor 1 receptor targeted therapeutics: novel compounds and novel treatment strategies for cancer medicine. Recent Pat Anticancer Drug Discov (2009) 1.46
Selective inhibition of casein kinase 1 epsilon minimally alters circadian clock period. J Pharmacol Exp Ther (2009) 1.46
Discovery of aminopyridine-based inhibitors of bacterial enoyl-ACP reductase (FabI). J Med Chem (2002) 1.44
Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med (2010) 1.43
Targeting the human EGFR family in esophagogastric cancer. Nat Rev Clin Oncol (2011) 1.43
Sixty-day all-cause mortality rates in patients treated for gastrointestinal cancers, in randomised trials, at the Royal Marsden Hospital. Eur J Cancer (2004) 1.43
Structure-guided inhibitor design for human FAAH by interspecies active site conversion. Proc Natl Acad Sci U S A (2008) 1.41
Randomized comparison of the stanford V regimen and ABVD in the treatment of advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244. J Clin Oncol (2009) 1.40
The role of myeloablation for lymphoma. N Engl J Med (2014) 1.30
Second cancer risk after chemotherapy for Hodgkin's lymphoma: a collaborative British cohort study. J Clin Oncol (2011) 1.30
Structural basis of transfer between lipoproteins by cholesteryl ester transfer protein. Nat Chem Biol (2012) 1.27
Multicenter randomized phase III trial comparing protracted venous infusion (PVI) fluorouracil (5-FU) with PVI 5-FU plus mitomycin in inoperable pancreatic cancer. J Clin Oncol (2002) 1.27
Improving long-term outcomes for patients with liver metastases from colorectal cancer. J Clin Oncol (2005) 1.24
Chemically programmed antibodies: endothelin receptor targeting CovX-Bodies. Bioorg Med Chem Lett (2006) 1.22
Fractionation of polymeric procyanidins from lowbush blueberry and quantification of procyanidins in selected foods with an optimized normal-phase HPLC-MS fluorescent detection method. J Agric Food Chem (2002) 1.22
Discovery of PF-04457845: A Highly Potent, Orally Bioavailable, and Selective Urea FAAH Inhibitor. ACS Med Chem Lett (2011) 1.21
Outcome of second-line chemotherapy for biliary tract cancer. Eur J Cancer (2012) 1.21
Predictive and prognostic biomarkers for targeted therapy in metastatic colorectal cancer. Clin Colorectal Cancer (2010) 1.20
Targeted therapy for gastric cancer. Curr Treat Options Oncol (2012) 1.19
Adjuvant treatment for resectable pancreatic cancer. J Clin Oncol (2005) 1.18
The use of biochemical and biophysical tools for triage of high-throughput screening hits - A case study with Escherichia coli phosphopantetheine adenylyltransferase. Chem Biol Drug Des (2010) 1.16
Recent data with anti-epidermal growth factor receptor antibodies and irinotecan in colon cancer. Clin Colorectal Cancer (2005) 1.16
Targeting the PI3K-AKT-mTOR signaling network in cancer. Chin J Cancer (2013) 1.15
Using predictive biomarkers to select patients with advanced colorectal cancer for treatment with epidermal growth factor receptor antibodies. J Clin Oncol (2008) 1.14
Modulation of human insulin receptor substrate-1 tyrosine phosphorylation by protein kinase Cdelta. Biochem J (2004) 1.13
The North American Menopause Society: from abstract to publication. Menopause (2008) 1.12
Description of the torcetrapib series of cholesteryl ester transfer protein inhibitors, including mechanism of action. J Lipid Res (2005) 1.09
Development of a diagnosis- and procedure-based risk model for 30-day outcome after pediatric cardiac surgery. J Thorac Cardiovasc Surg (2012) 1.09
Evaluating mesorectal lymph nodes in rectal cancer before and after neoadjuvant chemoradiation using thin-section T2-weighted magnetic resonance imaging. Int J Radiat Oncol Biol Phys (2007) 1.08
X-ray crystallographic and kinetic studies of human sorbitol dehydrogenase. Structure (2003) 1.08
Positive and negative regulatory role of insulin receptor substrate 1 and 2 (IRS-1 and IRS-2) serine/threonine phosphorylation. Biochemistry (2002) 1.08
The value of source data verification in a cancer clinical trial. PLoS One (2012) 1.07
Discordance between cancer prevalence and training: a need for an increase in oncology education. Clin Med (2013) 1.06
Contactin 4 as an autism susceptibility locus. Autism Res (2011) 1.05
East meets west in the treatment of gastric cancer. N Engl J Med (2007) 1.05
The frequency and pattern of cardiotoxicity observed with capecitabine used in conjunction with oxaliplatin in patients treated for advanced colorectal cancer (CRC). Eur J Cancer (2005) 1.05
Evidence for regulated monoacylglycerol acyltransferase expression and activity in human liver. J Lipid Res (2012) 1.05
Benzothiophene piperazine and piperidine urea inhibitors of fatty acid amide hydrolase (FAAH). Bioorg Med Chem Lett (2009) 1.03
Structural characterization of proline-rich tyrosine kinase 2 (PYK2) reveals a unique (DFG-out) conformation and enables inhibitor design. J Biol Chem (2009) 1.01
Molecular pharmacology of cancer therapy in human colorectal cancer by gene expression profiling. Cancer Res (2003) 1.00
Dose finding and early efficacy study of gemcitabine plus capecitabine in combination with bevacizumab plus erlotinib in advanced pancreatic cancer. J Clin Oncol (2009) 1.00
Gemcitabine, cisplatin and methylprednisolone for the treatment of patients with peripheral T-cell lymphoma: the Royal Marsden Hospital experience. Haematologica (2007) 1.00
Validation of the Royal Marsden hospital prognostic index in advanced esophagogastric cancer using individual patient data from the REAL 2 study. J Clin Oncol (2009) 0.98
The role of personalized medicine in metastatic colorectal cancer: an evolving landscape. Therap Adv Gastroenterol (2013) 0.98
Systemic treatment of gastric cancer. Eur J Gastroenterol Hepatol (2004) 0.98
Atmospheric tomography: a Bayesian inversion technique for determining the rate and location of fugitive emissions. Environ Sci Technol (2012) 0.97
Hypomorphic temperature-sensitive alleles of NSDHL cause CK syndrome. Am J Hum Genet (2010) 0.97